The Increasing Prevalence of Dry Eye Disease is Propelling the Market

Published: Feb 2025

The global dry eye disease market is anticipated to grow significantly during the forecast period (2024-2031). Market growth is driven by the rising prevalence of aging and increasing incidences of ocular surface diseases. Additionally, the increasing usage of the computer or digital screens may cause less blinking, which may contribute to symptoms of dry eye disease. The disease is particularly more common among women than in men. Furthermore, the increase in the elderly population is projected to increase, and eye-related disorders, such as dry eye will increase, propelling the market growth.

The market is segmented by product (artificial tears, anti-inflammatory drugs, punctual plugs, secretagogues, and others), by distribution channel (hospital pharmacies, independent pharmacies, drug stores, and online pharmacies), and by geography (North America, Europe, Asia-Pacific, the Rest of the World).

Market Dynamics

  • The artificial tears segment is anticipated to dominate the market during the forecast period, driven by the continuous launch of Over-The-Counter (OTC) medications to meet the rising demand from patients suffering from this condition. Additionally, an increase in regulatory approvals for the targeted treatment for dry eye is contributing to the segmental growth. 
  • The anti-inflammatory products segment is anticipated to hold a considerable share, owing to the better treatment outcomes, amongst the patient population.
  • North- America is anticipated to hold the largest market share, attributed to the increasing prevalence of dry eye disease in the region. Additionally, the rise in therapeutic measures is bolstering the market. 

Recent Developments 

  • In November 2024, Alcon announced positive topline results from the two pivotal Phase 3 clinical trials (COMET-2 and COMET-3) evaluating the efficacy and safety of AR-15512, for the treatment of signs and symptoms of dry eye disease (DED). The test enrolled more than 930 dry eye subjects, with the primary endpoint of the proportion of subjects with at least a 10-mm increase in unanesthetized Schirmer’s score, and statistical significance of p<0.0001. 
  • In October 2024, Aldeyra Therapeutics, Inc. announced the resubmission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for topical ocular reproxalap, an investigational new drug candidate, for the treatment of signs and symptoms of dry eye disease. 
  • In April 2024, Palatin Technologies, Inc., announced the results of its Phase 3 PL9643 MELODY-1 pivotal clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease (DED) at the American Society of Cataract and Refractive Surgery (ASCRS). The Intent-to-Treat (ITT) PL9643 treatment population demonstrated clinically meaningful and statistically significant results at the change from baseline to week 12 for the co-primary symptom endpoint of pain (p<0.025) and multiple exploratory secondary symptom endpoints. 

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/dry-eye-disease-market-size